Pacira BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pacira BioSciences, Inc.
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Axsome’s CRL was not the first from the US FDA for the nearly insoluble NSAID as sponsors try different technologies for delivering its pain relief quickly.
Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
- Specialty Pharmaceuticals
- Controlled Release
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Blue Acquisition Corp.
- DepoTech Corp.
- Flexion Therapeutics, Inc.
- myoscience, Inc.
- Pacira CryoTech, Inc.
- Pacira Pharmaceuticals, Inc.
- SkyePharma Inc.